TNFRSF8 and mesothelioma: Brentuximab vedotin was initially tested for the treatment of anaplastic large-cell lymphomas and Hodgkin disease [181] but, following a successful safety assessment in solid tumours [182], a phase II trial is now underway to evaluate its efficacy in patients with unresectable CD30+ mesothelioma (NCT03007030).